DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) is projected to release its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.15) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:00 AM ET.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Stock Down 4.8%

Shares of DMAC stock opened at $5.92 on Monday. The firm has a market cap of $306.00 million, a price-to-earnings ratio of -8.58 and a beta of 1.42. DiaMedica Therapeutics has a 52-week low of $3.19 and a 52-week high of $7.49. The company’s 50 day moving average is $6.73 and its 200 day moving average is $5.20.

Insiders Place Their Bets

In related news, major shareholder Jan Stahlberg bought 338,265 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were acquired at an average price of $6.00 per share, for a total transaction of $2,029,590.00. Following the completion of the transaction, the insider directly owned 7,654,045 shares in the company, valued at $45,924,270. This trade represents a 4.62% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 1,000,000 shares of company stock worth $5,958,598 in the last ninety days. Corporate insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On DiaMedica Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in DiaMedica Therapeutics by 3,710.3% in the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after buying an additional 8,274 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter worth approximately $49,000. Invesco Ltd. acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter worth approximately $54,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in DiaMedica Therapeutics in the 2nd quarter valued at approximately $56,000. Finally, BNP Paribas Financial Markets lifted its stake in DiaMedica Therapeutics by 24.4% during the second quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock worth $74,000 after purchasing an additional 3,709 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DMAC has been the topic of several research reports. Craig Hallum upped their target price on DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, July 18th. TD Cowen started coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Cowen assumed coverage on DiaMedica Therapeutics in a research report on Thursday, October 30th. They issued a “buy” rating on the stock. Finally, Lake Street Capital increased their price target on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, July 18th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, DiaMedica Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $12.33.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.